CM-PRP-HA provided significant pain relief and functional improvement.1
A prospective multicenter study was performed in patients with knee joint OA who did not respond to treatment with HA alone. Patients received 3 injections of the RegenPRP-HA combination prepared with Cellular Matrix® (CM-PRP-HA).
This study demonstrated that 3 injections of CM-PRP-HA is a new medical approach for patients who do not respond to treatment with HA alone and offers an alternative to knee surgery.1
83.6% success rate in patients who had an unsatisfactory clinical response to previous therapy with HA alone.1
Cellular Matrix technology: a safe, fast and novel treatment approach for OA of the knee.2
Fifty-three patients (90 knees), aged 39-80 years, suffering from knee osteoarthritis (Kellgren-Lawrence Grade I-III) were enrolled in a prospective randomized controlled clinical study comparing the clinical efficacy of Cellular Matrix (CM-PRP-HA) with two different types of HA: a non-crosslinked sodium hyaluronate (AV) and a non-crosslinked sodium hyaluronate combined with mannitol (OP).
The Cellular Matrix PRP-HA combination results in a longer and sustained clinical improvement than HA alone, and thus might be a useful tool for postponing arthroplasty.1,2
Prospective, randomized, dose-controlled, placebo-controlled, double-blind, triple-parallel study to compare the efficacy of intra-articular injections of RegenPRP or Hyaluronic Acid (HA) or normal saline (NS) solution for knee OA1
53 patients diagnosed with osteoarthritis, Ahlbäck Grade I-III, were randomly assigned to 3 groups.
3 weekly injections of either RegenPRP (31 knees), HA (29 knees), or NS (27 knees).
Follow-up: WOMAC and IKDC scores were recorded at 1, 2, 6 and 12 months
Significant improvement in function and pain at all time points compared to baseline.
Evaluate and quantify the effects of RegenPRP on the Quality-Of-Life (QoL) of knee OA patients2
72 patients with knee OA, Kellgren-Lawrence Grade 2 or 3
Patients had a total of 3 treatment sessions, with a RegenPRP injection given every 21 days. Patients were evaluated before the treatment and at 1, 3, 6 and 12 months from the last injection using the WOMAC, VAS at rest and VAS in movement scores.
Now is the time to change your patient’s life. Browse ressources and
get connected to treatment that is right for them.
Our Regional offices are